| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1262-3636(03)72787-6 |
| P698 | PubMed publication ID | 14502100 |
| P2093 | author name string | P J Grant | |
| P2860 | cites work | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. | Q54243732 |
| Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. | Q54314674 | ||
| Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. | Q54405733 | ||
| Banting lecture 1988. Role of insulin resistance in human disease | Q55921416 | ||
| Microalbuminuria and markers of the atherosclerotic process: the D.E.S.I.R. study | Q57312435 | ||
| Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL | Q57398955 | ||
| Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia | Q57607818 | ||
| Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes | Q67574961 | ||
| Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
| Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias | Q70865475 | ||
| Identification of active tissue factor in human coronary atheroma | Q71571184 | ||
| Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities | Q71745414 | ||
| Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study | Q71801510 | ||
| Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study | Q72235431 | ||
| Effect of biguanides and atromid on fibrinolysis | Q72242535 | ||
| von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome | Q72418116 | ||
| Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men | Q72690028 | ||
| Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study | Q73509474 | ||
| Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism | Q74138414 | ||
| Role of contact system activation in hemodialyzer-induced thrombogenicity | Q77155142 | ||
| FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE | Q78498046 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance | Q29619774 | ||
| Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies | Q33817201 | ||
| Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin | Q33899837 | ||
| AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER. | Q34257237 | ||
| WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. | Q34257361 | ||
| Platelet dysfunction in type 2 diabetes | Q34319534 | ||
| Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction | Q34545496 | ||
| Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. | Q35345503 | ||
| Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis | Q35939161 | ||
| The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots | Q36764995 | ||
| Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor | Q37020020 | ||
| Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide | Q37350905 | ||
| GPIIb-IIIa: the responsive integrin | Q37699902 | ||
| Metformin revisited: its actions and indications for use. | Q39486490 | ||
| Tissue factor pathway inhibitor and the revised theory of coagulation | Q40436668 | ||
| Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study | Q40874709 | ||
| The effects of metformin on cardiovascular risk factors | Q40927887 | ||
| Increased insulin concentrations in nondiabetic offspring of diabetic parents | Q41375124 | ||
| Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey | Q41914147 | ||
| Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance | Q42021393 | ||
| Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. | Q42665091 | ||
| Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. | Q43588414 | ||
| The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation | Q43833577 | ||
| Metformin decreases platelet superoxide anion production in diabetic patients | Q43982807 | ||
| Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes | Q44037432 | ||
| Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions | Q44155368 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study | Q44372241 | ||
| Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study | Q44734148 | ||
| Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects | Q47212016 | ||
| Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus | Q51003131 | ||
| The reaction between bovine brain tissue factor and factors VII and X. | Q51239402 | ||
| Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. | Q51553412 | ||
| Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. | Q51558539 | ||
| Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. | Q51558893 | ||
| Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. | Q51579869 | ||
| Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. | Q51598018 | ||
| The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. | Q51599538 | ||
| The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. | Q52869960 | ||
| Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients | Q52874727 | ||
| The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. | Q53992212 | ||
| P433 | issue | 4 Pt 2 | |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 6S44-52 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Diabetes and Metabolism | Q15758385 |
| P1476 | title | Beneficial effects of metformin on haemostasis and vascular function in man | |
| P478 | volume | 29 |
| Q90448263 | Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension |
| Q36117595 | Diabetes mellitus: new challenges and innovative therapies |
| Q33591379 | Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression |
| Q37737183 | Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature |
| Q41124317 | Effect of Preadmission Metformin Use on Clinical Outcome of Acute Respiratory Distress Syndrome among Critically Ill Patients with Diabetes |
| Q53831007 | Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. |
| Q36344151 | Effects and mechanism of moderate aerobic exercise on impaired fasting glucose improvement |
| Q33716793 | Folate supplementation reduces serum hsp70 levels in patients with type 2 diabetes |
| Q36323852 | Lowering blood glucose during hip surgery does not influence coagulation activation |
| Q37386201 | Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release |
| Q22250988 | Metformin and body weight |
| Q98619283 | Metformin as a Potential Agent in the Treatment of Multiple Sclerosis |
| Q35073367 | Metformin high dosage and bleeding episode: A clinical case study |
| Q24246552 | Metformin monotherapy for type 2 diabetes mellitus |
| Q89936654 | Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial |
| Q36104044 | Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus |
| Q97643486 | Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss |
| Q39100209 | Metformin: New Preparations and Nonglycemic Benefits |
| Q36715464 | Metformin: an old but still the best treatment for type 2 diabetes |
| Q36534692 | Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q59100784 | Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis |
| Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
| Q42337194 | Pharmacotherapy for Acute Respiratory Distress Syndrome: Limited Success to Date |
| Q92441493 | Pleiotropic Activity of Metformin and Its Sulfonamide Derivatives on Vascular and Platelet Haemostasis |
| Q35189544 | Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics |
| Q33754815 | Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study |
| Q36316335 | Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? |
| Q85040740 | Review article: Coagulation and fibrinolysis in diabetes |
| Q34620706 | Risk management in the treatment of type 2 diabetes with pioglitazone |
| Q37612236 | Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study. |
| Q35987411 | Rosiglitazone RECORD study: glucose control outcomes at 18 months |
| Q37222216 | Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibr |
| Q37180980 | Targeting the AMPK pathway for the treatment of Type 2 diabetes |
| Q64084410 | The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome |
| Q82861391 | [Effects of metformin on endothelial dysfunction of the renal circulation resulting from acute hyperglycemia in non-diabetic rabbits] |
Search more.